4503

Astellas Pharma Inc.

アステラス製薬株式会社
Pharmaceutical
Astellas Pharma Inc. manufactures, markets, imports, and exports pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia; VYLOY, a treatment for gastric cancer; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also provides VEOZAH, a treatment for vasomotor symptoms due to menopause; IZERVAY, a treatment for geographic atrophy secondary to age-related macular degeneration; EVRENZO, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf, an immunosuppressant. It has a research collaboration with xFOREST Therapeutics to develop RNA-targeted therapies and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize an integrated diabetes self-management solution. It offers its products to oncology, ophthalmology, urology, immunology, and women's health areas. The company was formerly known as Yamanouchi Pharmaceutical Co. Ltd. and changed its name to Astellas Pharma Inc. in April 2005. Astellas Pharma Inc. was founded in 1923 and is headquartered in Chuo, Japan.
← Companies
Price
¥2,283
Market Cap
¥4.1T
Ent. Value
¥4.4T
Net Debt
−¥284.3B
Shares Out.
1.8B
P / E
14.0×
EV / EBIT
11.5×
P / Book
2.24×
P / NCAV
N/M
Div. Yield
1.71%
Financials
Metric FY 2025
TDnet 		FY 2024
EDINET ↗ 		FY 2023
EDINET ↗ 		FY 2022
EDINET ↗ 		FY 2021
EDINET ↗
Net Sales ¥2,139.2B ¥1,912.3B ¥1,603.7B ¥1,518.6B ¥1,296.2B
Cost of Sales ¥408.4B ¥349.2B ¥292.5B ¥288.4B ¥253.0B
Gross Profit ¥1,730.8B ¥1,563.1B ¥1,311.2B ¥1,230.3B ¥1,043.2B
SG&A ¥860.3B ¥843.0B ¥740.1B ¥630.3B ¥548.8B
Operating Income ¥382.6B ¥41.0B ¥25.5B ¥133.0B ¥155.7B
Non-Operating Income — ¥7.9B ¥11.5B ¥8.1B ¥6.1B
Interest Income — ¥6.8B ¥8.8B ¥5.2B ¥794M
Non-Operating Expenses — ¥17.7B ¥12.0B ¥8.8B ¥4.9B
Interest Expense — ¥14.0B ¥7.4B ¥3.2B ¥2.3B
Pre-tax Income ¥376.6B ¥31.2B ¥25.0B ¥132.4B ¥156.9B
Net Income (owners) ¥291.5B ¥50.7B ¥17.0B ¥98.7B ¥124.1B
Comprehensive Income — ¥48.9B ¥205.6B ¥205.3B ¥208.1B
EPS ¥162.77 ¥28.35 ¥9.51 ¥54.24 ¥67.08
Shares Outstanding — 1.81B 1.81B 1.81B 1.83B
Shares Issued (total) — 1.81B 1.81B 1.81B 1.84B
Treasury Shares — 0.5M 0.6M 0.8M 0.9M